Did Embecta's 56% Fall Catch You Out? What Investors Missed

If you had been weighing Embecta against other healthcare ideas in October 2025 and decided to sit it out, the past year looked very different for you than for those who bought in. For Embecta shareholders, the loss over the past year was 56.1%, including dividends. With lawsuits now alleging that earlier guidance ignored weakness in the U.S. pen needle business, which assumptions or recorded warnings could an investor have checked at the start?

Embecta has already moved. See which of 29 high quality undervalued stocks still trade below our estimates.

The Two Embecta Stories Investors Had To Weigh

The shares cost US$13.59 at the start, and Embecta sat between two very different stories about where its diabetes hardware business could go next.

The bullish case saw a Fair Value of US$16.67, a price implied by forecasts, built on GLP-1 partnerships expanding global reach and profit margins rising toward 16.7% over a 3 year stretch.

The bearish view pointed to a Fair Value of US$11.83, with pressure from reimbursement cuts and newer diabetes technologies seen as long term threats to legacy pen needles.

What The Results Changed For The Embecta Thesis

Embecta’s later filings showed Q3 2026 revenue of US$271.7 million versus US$295.5 million a year earlier, with net income lower and net margin moving from 15.4% to 7.8%. That challenged the previously discussed 16.7% margin path in the bullish case. Securities class actions over guidance on the U.S. pen needle line further supported the more cautious view.

The episode hinged on one assumption: that pen needle demand and pricing would hold up. For any healthcare hardware stock, you would now check segment level trends and margin guidance against later reported revenue, profit and net margin for that specific product line.

What Embecta's Lower Price Asks You To Believe

Embecta trades at US$5.68 today, and the selected Narrative’s Fair Value sits below the current price. That view rests on the idea that the market is already paying up for GLP 1 partnerships, auto-injectors and the Owen Mumford deal.

The key question for you is whether ongoing U.S. pen needle weakness and any margin pressure from diversification are fully reflected in the lower share price.

"The current numbers and litigation overhang imply a share price that still embeds generous expectations for Embecta’s diversification and margin recovery, which this bearish narrative views as overvalued."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Which Company Could Surprise You Next?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 27% below our estimate - relies on demand for specialised chips powering artificial intelligence infrastructure and tools.
• Company 2 - 30% below our estimate - manages a sizable resource portfolio while navigating operational challenges and jurisdictional uncertainty.
• Company 3 - 46% below our estimate - expands transactional platforms with digital payment services and capital-return programs for investors.

Those are three of them. See every one of the 25 solid balance sheet companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com